Resveratrol Inhibits Macrophage Glucose Metabolism Reprogramming and Inflammatory Activation to Delay COPD Progression Through the TLR4/HK2 Pathway
Resveratrol hemmt die Reprogrammierung des Glukosestoffwechsels und die inflammatorische Aktivierung von Makrophagen zur Verzögerung der COPD-Progression über den TLR4/HK2-Signalweg
Journal of Cellular Physiology · 2026-09 · 241 (9)
DOI: 10.1002/jcp.70227 ↗Auf einen Blick
In einem COPD-Mausmodell und in LPS-stimulierten RAW264.7-Makrophagen verringerte Resveratrol Entzündung und M1-Polarisation. Die Effekte wurden mit einer Hemmung des TLR4/HK2-Signalwegs verknüpft.
Fragestellung
Ob Resveratrol die COPD-Progression durch Modulation der inflammatorischen Aktivierung und der glykolytischen Reprogrammierung von Makrophagen über den TLR4/HK2-Signalweg verzögert.
Methode
COPD-Mausmodell mit LPS-Instillation und Zigarettenrauch; Behandlung mit Resveratrol 50 mg/kg. In vitro LPS-stimulierte RAW264.7-Makrophagen mit Resveratrol, TLR4-Überexpression oder HK2-Silencing.
Ergebnisse
Resveratrol verbesserte die Lungenschädigung, senkte inflammatorische Scores, MLI und DI sowie BALF-Entzündungszellzahlen. In Makrophagen sanken NO, IL-6, TNF-α, Glukoseaufnahme, Laktat und ECAR; OCR stieg.
Schlussfolgerung der Autor:innen
Resveratrol vermindert die inflammatorische Aktivierung, M1-Polarisation und glykolytische Reprogrammierung von Makrophagen teilweise über die Hemmung des TLR4/HK2-Signalwegs und könnte die COPD-Progression verzögern.
Kernaussagen
- Im COPD-Mausmodell nahm Lungenschädigung unter Resveratrol ab.
- Resveratrol senkte Entzündungsmediatoren und M1-Polarisation von Makrophagen.
- TLR4-Überexpression hob die schützenden Effekte von Resveratrol teilweise auf.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular Physiology, online erschienen am 06.09.2026. Verfasst von Zhu Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China. Hauptthemen laut MEDLINE: Toll-Like Receptor 4, Resveratrol, Pulmonary Disease, Chronic Obstructive, Macrophages. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: COPD
Abstract (Originalsprache)
Chronic obstructive pulmonary disease (COPD) is characterized by persistent airway inflammation and metabolic dysregulation in immune cells, particularly macrophages. This study aimed to determine whether resveratrol (RES) delays COPD progression by modulating macrophage inflammatory activation and glycolytic reprogramming through the Toll‐like receptor 4/hexokinase 2 (TLR4/HK2) signaling pathway. A COPD mouse model was established by lipopolysaccharide (LPS) instillation combined with cigarette smoke exposure, followed by treatment with RES at 50 mg/kg. Lung histopathology, mean linear intercept (MLI), destructive index (DI), bronchoalveolar lavage fluid (BALF) inflammatory cell counts, cytokine levels, macrophage polarization, and TLR4/HK2 pathway protein expression were assessed. In vitro, LPS‐stimulated RAW264.7 macrophages were treated with RES, with or without TLR4 overexpression and HK2 silencing, to evaluate inflammatory responses, M1 polarization, glycolytic activity, and mitochondrial respiration. RES significantly alleviated lung tissue injury, decreased inflammatory scores, MLI, and DI, and reduced BALF inflammatory cell counts in COPD mice. RES also decreased inflammatory cytokine levels, suppressed macrophage M1 polarization, and downregulated TLR4, p‐p65, and HK2 expression. In LPS‐stimulated macrophages, RES reduced NO, IL‐6, TNF‐α, glucose uptake, lactate production, and ECAR, while improving OCR. TLR4 overexpression reversed the inhibitory effects of RES on inflammatory activation, M1 polarization, glycolytic reprogramming, and HK2 expression, whereas HK2 silencing partially restored the protective effects of RES under TLR4 overexpression. RES alleviates macrophage inflammatory activation, M1 polarization, and glycolytic reprogramming, in part through inhibition of the TLR4/HK2 pathway, suggesting its therapeutic potential for delaying COPD progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China.
- Department of Emergency Medicine, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China.
- Clinical Section 1, Mental Health Dept (Addiction Medicine Center), The First Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China.
- Office of Medical Administration, Hebei Hospital of Xuanwu Hospital of Capital Medical University, Shijiazhuang, Hebei Province, China.
- Department of Respiratory Medicine, The Third People's Hospital of Hengshui, Hengshui, Hebei Province, China.
ORCID-Profile: Kun Li
Zitieren
APA
Li, Z., Zhang, B., Li, K., Yan, J., Li, N., Sun, L., & Zhao, W. (2026). Resveratrol Inhibits Macrophage Glucose Metabolism Reprogramming and Inflammatory Activation to Delay COPD Progression Through the TLR4/HK2 Pathway. Journal of Cellular Physiology, 241(9). https://doi.org/10.1002/jcp.70227
Vancouver
Li Z, Zhang B, Li K, Yan J, Li N, Sun L, et al. Resveratrol Inhibits Macrophage Glucose Metabolism Reprogramming and Inflammatory Activation to Delay COPD Progression Through the TLR4/HK2 Pathway. Journal of Cellular Physiology. 2026;241(9). doi:10.1002/jcp.70227
BibTeX
@article{Li2026,
author = {Li, Zhu and Zhang, Bin and Li, Kun and Yan, Jinghui and Li, Na and Sun, Lijuan and Zhao, Wei},
title = {Resveratrol Inhibits Macrophage Glucose Metabolism Reprogramming and Inflammatory Activation to Delay COPD Progression Through the TLR4/HK2 Pathway},
journal = {Journal of Cellular Physiology},
year = {2026},
volume = {241},
number = {9},
doi = {10.1002/jcp.70227}
}
EUVIMED